Ara
Toplam kayıt 14, listelenen: 1-10
Real-world data from the Turkish national chronic lymphocytic leukemia registry
(CIG Media Group, 2020)
Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were ...
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
(Elsevier Science Inc, 2020)
Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ...
Artificial intelligence to assist better myeloma care, is it the time?
(Cıg Media Group, 2019)
Myeloma treatment made an enormous progress during the last decade. Armamentarium is grossly enlarging each year in the field of treatment. Parallel to the progress achieved to provide better care for myeloma patients, ...
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
(CIG Media Group, 2021)
Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ...
Turkish acute lymphoblastic leukemia registry, retrospective phase data
(The American Society of Hematology, 2019)
Background and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in ...
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
(The American Society of Hematology, 2019)
Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ...
Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction
(CIG Media Group, 2022)
Introduction: There is a paucity of data regarding the best practice to institute iv Daratumumab (D) in morbid obese patients regarding the infusion rate and duration, optimal dosing, and ideal way to cope with the infusion ...
Successful use of frontline daratumumab lenalidomide and dexamethasone in transplant ineligible frail patients with moderate renal failure at the time of presentation
(CIG Media Group, 2022)
Introduction: Treatment of the elderly patients who have varying degrees of renal failure at the time of presentation, both due to the underlying plasma cell dyscrasia or the other comorbidities is a true challenge regarding ...
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
(American Society of Hematology, 2022)
Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T
cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ...
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
(American Society of Hematology, 2022)
Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ...